Table 1.
Participants demographic characteristics. The study population includes volunteers who provided blood samples after the first dose and after the second dose (Whole study population). Participants who provided at least one blood sample following the second vaccination were subject to analysis (Population in model).
| Characteristics | Whole study population (n=4359) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Population in model (n=4314) | ||||||||||
| Total | Before2Dose | week1–2 | week3–4⁎ | week5–8* | week9–12 | week13–16 | week17–20 | week21+ | ||
| Age, median (IQR) | 31 (24–41) | 34(29-43) | 32(27-42) | 35(28-45) | 30(23-42) | 24(22-32) | 28(23-38) | 31(25-41) | 33(29-42) | |
| Age n (%) | 18–27 | 1717 (39.4) | 207(20.6) | 183(29.7) | 459(24.3) | 163(43.6) | 460(63.6) | 556(48.8) | 142(36.5) | 53(18.7) |
| 27–38 | 1235 (28.3) | 369(36.8) | 215(34.8) | 621(32.9) | 91(24.3) | 161(22.3) | 289(25.4) | 114(29.3) | 132(46.5) | |
| 38–47 | 748 (17.2) | 247(24.6) | 141(22.9) | 402(21.3) | 54(14.4) | 67(9.3) | 182(16.0) | 78(20.1) | 56(19.7) | |
| ≥48 | 659 (15.1) | 153(15.3) | 78(12.6) | 406(21.5) | 66(17.7) | 35(4.8) | 111(9.8) | 55(14.1) | 43(15.1) | |
| Sex n (%) | male | 1117 (25.6) | 239(23.8) | 172(27.9) | 556(29.5) | 85(22.7) | 170(23.5) | 235(20.7) | 85(21.9) | 54(19.0) |
| female | 3242 (74.4) | 764(76.2) | 445(72.1) | 1332(70.6) | 289(77.3) | 553(76.5) | 903(79.3) | 304(78.1) | 230(81.0) | |
| BMI n (%) | ≤18.5 | 536 (12.3) | 99(9.9) | 62(10.0) | 174(9.2) | 44(11.8) | 129(17.8) | 156(13.7) | 42(10.8) | 34(12.0) |
| 18.5–23.9 | 3093 (71.2) | 626(62.4) | 374(60.6) | 1137(60.7) | 237(63.5) | 478(66.1) | 731(64.2) | 270(69.4) | 193(68.0) | |
| ≥23.9 | 712 (16.5) | 268(26.7) | 177(28.9) | 562(30.0) | 92(24.7) | 116(16.1) | 251(22.1) | 77(17.8) | 57(20.0) | |
| Body condition n (%) | health | 1818 (43.2) | 543(54.1) | 382(62.0) | 1252(66.3) | 135(36.1) | 129(17.8) | 262(23.0) | 136(35.0) | 71(25.0) |
| comorbidity | 2386 (56.8) | 460(45.9) | 235(38) | 636(33.7) | 239(63.9) | 594(82.2) | 876(77.0) | 253(65.0) | 213(75.0) | |
| Seropositivity N (%) | NAbs | 4817(72.5) | 140(12.5) | 525(84.4) | 1802(94.6) | 336(89.8) | 625(86.3) | 922(81.0) | 301(77.3) | 166(58.5) |
| IgG | 4753(73.5) | 108(9.6) | 517(83.1) | 179(94.1) | 339(90.6) | 622(85.9) | 939(82.5) | 296(76.1) | 144(50.7) | |
| IgM | 1465(22.0) | 156(13.6) | 292(46.9) | 875(46.0) | 57(15.2) | 35(4.8) | 29(0.8) | 13(3.3) | 8(2.8) | |
n: Number of participants; N:Sample size;
⁎
:Some individuals did not provide online survey.